Back to Search Start Over

Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies

Authors :
Qian-Qian Man
Yi-lin Yang
Wei Wang
Qi-tao Huang
Mei Zhong
Jia Hu
Yanhong Yu
Yue-Mei Zhang
Source :
Oncotarget
Publication Year :
2016

Abstract

// Qi-Tao Huang 1 , Qian-Qian Man 2 , Jia Hu 2 , Yi-Lin Yang 2 , Yue-Mei Zhang 2 , Wei Wang 1 , Mei Zhong 1 , Yan-Hong Yu 1 1 Division of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China 2 Southern Medical University, Guangzhou, 510515, China Correspondence to: Qi-Tao Huang, email: 15920454515@163.com Mei Zhong, email: zhongm1960@163.com Keywords: cervical cancer, inflammatory, neutrophil, lymphocyte, prognosis Received: September 01, 2016 Accepted: January 06, 2017 Published: February 06, 2017 ABSTRACT Background and aims: The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in cervical cancer are controversial. We conducted this meta-analysis to obtain a more accurate assessment of prognostic significance of NLR in cervical cancer. Results: A total of 9 studies, consisting of 2,804 patients, were selected in this meta-analysis. Our pooled results showed that high pre-treatment NLR level was significantly associated with poorer overall survival (HR: 1.88, 95% CI 1.30–2.73) and shorter progression free survival (HR 1.65, 95% CI 1.18–2.29). Additionally, increased NLR was also significantly correlated with tumor size (OR 2.05, 95% CI 1.14–3.65), advanced FIGO stage (OR 2.12, 95% CI1.28–3.49) and lymph node involvement (OR 2.24, 95% CI 1.65–3.04). Materials and Methods: We conducted a systematic literature search using the electronic databases PubMed, Web of Science, and Embase up to May 2016.Statistical analysis was performed using Stata 10.0. Conclusions: Elevated pretreatment NLR could serve as a predicative factor of poor prognosis for cervical cancer patients.

Details

ISSN :
19492553
Volume :
8
Issue :
10
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....dcb3e1eeac2f9c79301883499cd925a9